04/04/2023 – AB Science today provides an update on the schedule for the evaluation by the European Medicines Agency (EMA) and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
16/03/2023 – Presentation of the AB Science Microtubule Destabilizer Agents platform webcast
15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform
13/03/2023 – AB Science today announces a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute myeloid leukemia (AML)
28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy
31/01/2023 – AB Science announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB)
29/12/2022 – AB Science announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA)
27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS)
22/12/2022 – AB Science announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB)
13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis